

Biosimilars: Global Markets

<https://marketpublishers.com/r/BDF3F38FC4FEN.html>

Date: March 2025

Pages: 219

Price: US\$ 4,650.00 (Single User License)

ID: BDF3F38FC4FEN

Abstracts

Report Scope

This report provides the current and future market potential of biosimilars, with market projections through 2029; and it includes a detailed analysis of the drivers, restraints and opportunities in the biosimilars market. The report also covers the competitive environment of the biosimilars industry and features a product analysis.

For this analysis, the market for biosimilars is segmented based on product type, therapeutic application and region. Based on product type, it is segmented into monoclonal antibodies, recombinant growth factors, recombinant hormones, fusion protein and others (such as LMWHs and interferons). Based on therapeutic application, the market is segmented into the following: cancer and related disorders, autoimmune and inflammatory diseases, diabetes, anemia, growth hormone deficiency and other diseases. Based on geographical region, the biosimilars market is segmented into the following: North America, Europe, Asia-Pacific and the Rest of the World (RoW). The North American region includes the U.S., Canada and Mexico. Europe includes Germany, the U.K., Italy, France, Spain and the Rest of Europe; Asia-Pacific includes China, Japan, India, Australia, South Korea and the Rest of Asia-Pacific. For market estimate data, 2021 and 2022 serve as the historical years, 2023 as the base year, and 2029 as the forecast year.

The report provides company profiles of key players in the biosimilars market that feature detailed information about each organization's business segments, financials, product portfolios and recent developments.

Report Includes

142 data tables and 74 additional tables

An analysis of the global market trends for biosimilars, with historic revenue data (sales figures) from 2021 and 2022, estimates for 2023, forecast for 2024, and projected CAGRs through 2029

Estimates of the market size and revenue growth prospects, along with a market share analysis by product type and sub-type, therapeutic application, and region

Facts and figures pertaining to the market dynamics, advances in existing biosimilars, regulations and the impact of macroeconomic factors

Review of the industry structure, emerging trends and developments, clinical trials and approvals, and new product

Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses

An analysis of key patent publications, grants and applications in biosimilars

Analysis of the competitive landscape featuring companies' market shares, strategic alliances, M&A activity and a venture funding outlook

Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and ESG scores and practices of leading companies

Profiles of the market leaders, including Amgen Inc., Sandoz Group AG, Biocon Biologics Ltd., Pfizer Inc., and Teva Pharmaceutical Industries Ltd.

Contents

CHAPTER 1 EXECUTIVE SUMMARY

Market Outlook
Scope of Report
Market Insights

CHAPTER 2 MARKET OVERVIEW

Introduction
Terminology of Biosimilars
Key Terms in Biosimilars
WHO Guidelines on Evaluation of Biosimilars
Pharmacovigilance/Post-Approval Monitoring
Biosimilars Vs. Biobetters
Popular Types of Biosimilars
Recombinant Hormones
Recombinant Growth Factors
Monoclonal Antibodies (mAbs)
Fusion Proteins
Interferons
Low Molecular Weight Heparins (LMWHs)

CHAPTER 3 MARKET DYNAMICS

Introduction
Market Drivers
Patent Expirations of Major Biologics
Cost-effectiveness and Healthcare Savings
Market Restraints
Intellectual Property and Legal Issues
Manufacturing and Supply Chain Complexities
Market Opportunities
Increasing Access, Adoption and Awareness
Emerging Markets

CHAPTER 4 EMERGING TECHNOLOGIES

Advanced Analytical Techniques
Single-use Bioreactors
Cell Line Engineering and Expression Systems

CHAPTER 5 MARKET SEGMENTATION ANALYSIS

Segmentation Breakdown
Global Biosimilars Market, by Product Type
Monoclonal Antibodies
Recombinant Growth Factors
Recombinant Hormones
Fusion Protein
Others
Global Biosimilars Market, by Therapeutic Application
Cancer and Related Disorders
Autoimmune and Inflammatory Diseases
Diabetes
Anemia
Growth Hormone Deficiency
Other Diseases
Geographic Breakdown
Global Biosimilars Market, by Region
Market Size and Forecast
North America
Europe
Asia-Pacific
Rest of the World (RoW)

CHAPTER 6 COMPETITIVE LANDSCAPE AND PATENT ANALYSIS

Overview
Key Market Leaders
Emerging Players
Strategic Analysis
Challenges and Future Trends
Patent Analysis
Patent Regulations in Favor of Branded Biologics
Market Exclusivity

CHAPTER 7 REGULATORY ASPECTS

Overview

Biosimilar Regulations in Europe

Biosimilar Regulations in the U.S.

Principle of Exclusivity

Biosimilar Regulations in China

CHAPTER 8 SUSTAINABILITY IN THE GLOBAL BIOSIMILARS MARKET: AN ESG PERSPECTIVE

Introduction to ESG

ESG Performance in the Market

ESG Practices in the Biosimilars Industry

Environmental Performance

Concluding Remarks from BCC Research

CHAPTER 9 APPENDIX

Research Methodology

Sources

Abbreviations

Company Profiles

ACCORD BIOPHARMA INC.

ALVOTECH

AMGEN INC.

AMNEAL PHARMACEUTICALS LLC.

BIOCON BIOLOGICS LTD.

BIOGEN

CELLTRION INC.

COHERUS BIOSCIENCES

FRESENIUS KABI AG

LILLY

PFIZER INC.

SAMSUNG BIOEPIS

SANDOZ GROUP AG

TEVA PHARMACEUTICAL INDUSTRIES LTD.

VIATRIS INC.

List Of Tables

LIST OF TABLES

Summary Table : Global Biosimilars Market, by Region, Through 2029

Table 1 : Differences Between Generic and Biosimilar Drugs

Table 2 : Terminology Related to Biosimilars

Table 3 : Biosimilars Vs. Biobetters

Table 4 : Examples of Approved Biobetters

Table 5 : Representative Biobetters in Clinical Trials

Table 6 : Key Developments in Biosimilar Recombinant Hormones

Table 7 : Key Developments in Biosimilar Recombinant Growth Factors

Table 8 : Key Developments in Biosimilar Monoclonal Antibodies

Table 9 : Key Developments in Enbrel (Etanercept) Biosimilars

Table 10 : Key Developments in Biosimilar Interferons

Table 11 : Key Developments in LMWHs Biosimilars

Table 12 : Global Biosimilars Market, by Product Type, Through 2029

Table 13 : EMA Approved Biosimilar Monoclonal Antibodies

Table 14 : FDA Approved Biosimilar Monoclonal Antibodies

Table 15 : Global Biosimilar Monoclonal Antibodies Market, by Region, Through 2029

Table 16 : Global Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029

Table 17 : Global Trastuzumab Biosimilars Market, by Region, Through 2029

Table 18 : Global Rituximab Biosimilars Market, by Region, Through 2029

Table 19 : Global Adalimumab Biosimilars Market, by Region, Through 2029

Table 20 : Global Bevacizumab Biosimilars Market, by Region, Through 2029

Table 21 : Global Infliximab Biosimilars Market, by Region, Through 2029

Table 22 : EMA Approved Recombinant Growth Factors Biosimilars

Table 23 : FDA Approved Recombinant Growth Factors Biosimilars

Table 24 : Global Recombinant Growth Factors Biosimilars Market, by Region, Through 2029

Table 25 : Global Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029

Table 26 : Global Filgrastim Biosimilars Market, by Region, Through 2029

Table 27 : Global Epoetin Alfa Biosimilars Market, by Region, Through 2029

Table 28 : Global Pegfilgrastim Biosimilars Market, by Region, Through 2029

Table 29 : EMA Approved Recombinant Hormones Biosimilars

Table 30 : FDA Approved Recombinant Hormones Biosimilars

Table 31 : Global Recombinant Hormones Biosimilars Market, by Region, Through 2029

Table 32 : Global Recombinant Hormones Biosimilars Market, by Product Type, Through 2029

Table 33 : Global Insulin Biosimilars Market, by Region, Through 2029

Table 34 : Global Somatotropin Biosimilars Market, by Region, Through 2029

Table 35 : Global Teriparatide Biosimilars Market, by Region, Through 2029

Table 36 : Global Follitropin Alfa Biosimilars Market, by Region, Through 2029

Table 37 : Global Fusion Protein Biosimilars Market, by Region, Through 2029

Table 38 : Global Other Biosimilars Market, by Region, Through 2029

Table 39 : Global Biosimilars Market, by Therapeutic Application, Through 2029

Table 40 : Global Cancer and Related Disorders Market in Biosimilars, by Region, Through 2029

Table 41 : Global Autoimmune and Inflammatory Diseases Market in Biosimilars, by Region, Through 2029

Table 42 : Global Diabetes Market in Biosimilars, by Region, Through 2029

Table 43 : Global Anemia Market in Biosimilars, by Region, Through 2029

Table 44 : Global Growth Hormone Deficiency Market in Biosimilars, by Region, Through 2029

Table 45 : Global Other Diseases Market in Biosimilars, by Region, Through 2029

Table 46 : Global Biosimilars Market, by Region, Through 2029

Table 47 : North American Biosimilars Market, by Country, Through 2029

Table 48 : North American Biosimilars Market, by Product Type, Through 2029

Table 49 : North American Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029

Table 50 : North American Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029

Table 51 : North American Recombinant Hormones Biosimilars Market, by Product Type, Through 2029

Table 52 : North American Biosimilars Market, by Therapeutic Application, Through 2029

Table 53 : Biosimilar Approvals in the U.S.

Table 54 : U.S. Biosimilars Market, by Product Type, Through 2029

Table 55 : U.S. Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029

Table 56 : U.S. Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029

Table 57 : U.S. Recombinant Hormones Biosimilars Market, by Product Type, Through 2029

Table 58 : U.S. Biosimilars Market, by Therapeutic Application, Through 2029

Table 59 : Canadian Biosimilars Market, by Product Type, Through 2029

Table 60 : Canadian Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029

Table 61 : Canadian Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029

Table 62 : Canadian Recombinant Hormones Biosimilars Market, by Product Type, Through 2029

Table 63 : Canadian Biosimilars Market, by Therapeutic Application, Through 2029

Table 64 : Mexican Biosimilars Market, by Product Type, Through 2029

Table 65 : Mexican Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029

Table 66 : Mexican Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029

Table 67 : Mexican Recombinant Hormones Biosimilars Market, by Product Type, Through 2029

Table 68 : Mexican Biosimilars Market, by Therapeutic Application, Through 2029

Table 69 : Biosimilar Approvals in Europe

Table 70 : European Biosimilars Market, by Country, Through 2029

Table 71 : European Biosimilars Market, by Product Type, Through 2029

Table 72 : European Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029

Table 73 : European Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029

Table 74 : European Recombinant Hormones Biosimilars Market, by Product Type, Through 2029

Table 75 : European Biosimilars Market, by Therapeutic Application, Through 2029

Table 76 : German Biosimilars Market, by Product Type, Through 2029

Table 77 : German Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029

Table 78 : German Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029

Table 79 : German Recombinant Hormones Biosimilars Market, by Product Type, Through 2029

Table 80 : German Biosimilars Market, by Therapeutic Application, Through 2029

Table 81 : U.K. Biosimilars Market, by Product Type, Through 2029

Table 82 : U.K. Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029

Table 83 : U.K. Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029

Table 84 : U.K. Recombinant Hormones Biosimilars Market, by Product Type, Through 2029

2029

Table 85 : U.K. Biosimilars Market, by Therapeutic Application, Through 2029

Table 86 : French Biosimilars Market, by Product Type, Through 2029

Table 87 : French Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029

Table 88 : French Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029

Table 89 : French Recombinant Hormones Biosimilars Market, by Product Type, Through 2029

Table 90 : French Biosimilars Market, by Therapeutic Application, Through 2029

Table 91 : Italian Biosimilars Market, by Product Type, Through 2029

Table 92 : Italian Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029

Table 93 : Italian Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029

Table 94 : Italian Recombinant Hormones Biosimilars Market, by Product Type, Through 2029

Table 95 : Italian Biosimilars Market, by Therapeutic Application, Through 2029

Table 96 : Spanish Biosimilars Market, by Product Type, Through 2029

Table 97 : Spanish Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029

Table 98 : Spanish Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029

Table 99 : Spanish Recombinant Hormones Biosimilars Market, by Product Type, Through 2029

Table 100 : Spanish Biosimilars Market, by Therapeutic Application, Through 2029

Table 101 : Rest of European Biosimilars Market, by Product Type, Through 2029

Table 102 : Rest of European Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029

Table 103 : Rest of European Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029

Table 104 : Rest of European Recombinant Hormones Biosimilars Market, by Product Type, Through 2029

Table 105 : Rest of European Biosimilars Market, by Therapeutic Application, Through 2029

Table 106 : Asia-Pacific Biosimilars Market, by Country, Through 2029

Table 107 : Asia-Pacific Biosimilars Market, by Product Type, Through 2029

Table 108 : Asia-Pacific Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029

Table 109 : Asia-Pacific Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029

Table 110 : Asia-Pacific Recombinant Hormones Biosimilars Market, by Product Type, Through 2029

Table 111 : Asia-Pacific Biosimilars Market, by Therapeutic Application, Through 2029

Table 112 : Biosimilar Approvals in China

Table 113 : Chinese Biosimilars Market, by Product Type, Through 2029

Table 114 : Chinese Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029

Table 115 : Chinese Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029

Table 116 : Chinese Recombinant Hormones Biosimilars, by Product Type, Through 2029

Table 117 : Chinese Biosimilars Market, by Therapeutic Application, Through 2029

Table 118 : Japanese Biosimilars Market, by Product Type, Through 2029

Table 119 : Japanese Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029

Table 120 : Japanese Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029

Table 121 : Japanese Recombinant Hormones Biosimilars Market, by Product Type, Through 2029

Table 122 : Japanese Biosimilars Market, by Therapeutic Application, Through 2029

Table 123 : Indian Biosimilars Market, by Product Type, Through 2029

Table 124 : Indian Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029

Table 125 : Indian Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029

Table 126 : Indian Recombinant Hormones Biosimilars Market, by Product Type, Through 2029

Table 127 : Indian Biosimilars Market, by Therapeutic Application, Through 2029

Table 128 : Australian Biosimilars Market, by Product Type, Through 2029

Table 129 : Australian Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029

Table 130 : Australian Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029

Table 131 : Australian Recombinant Hormones Biosimilars Market, by Product Type, Through 2029

Table 132 : Australian Biosimilars Market, by Therapeutic Application, Through 2029

Table 133 : South Korean Biosimilars Market, by Product Type, Through 2029

Table 134 : South Korean Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029

Table 135 : South Korean Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029

Table 136 : South Korean Recombinant Hormones Biosimilars Market, by Product Type, Through 2029

Table 137 : South Korean Biosimilars Market, by Therapeutic Application, Through 2029

Table 138 : Rest of Asia-Pacific Biosimilars Market, by Product Type, Through 2029

Table 139 : Rest of Asia-Pacific Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029

Table 140 : Rest of Asia-Pacific Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029

Table 141 : Rest of Asia-Pacific Recombinant Hormones Biosimilars Market, by Product Type, Through 2029

Table 142 : Rest of Asia-Pacific Biosimilars Market, by Therapeutic Application, Through 2029

Table 143 : RoW Biosimilars Market, by Product Type, Through 2029

Table 144 : RoW Biosimilar Monoclonal Antibodies Market, by Product Type, Through 2029

Table 145 : RoW Recombinant Growth Factors Biosimilars Market, by Product Type, Through 2029

Table 146 : RoW Recombinant Hormones Biosimilars Market, by Product Type, Through 2029

Table 147 : RoW Biosimilars Market, by Therapeutic Application, Through 2029

Table 148 : Select Strategic Alliances in the Biosimilars Industry, 2022-2024

Table 149 : Leading Biosimilars Companies, by Revenue, 2023

Table 150 : U.S. Patent Expirations and Biosimilars, 2024

Table 151 : Pending Biosimilar Patent Litigation, 2024

Table 152 : FDA Guidelines on Biosimilars, February 2021

Table 153 : Biosimilar Products Approved in China, 2024

Table 154 : Key Focus Areas in ESG Metrics

Table 155 : ESG Rankings for Key Players in Biosimilars Market, 2024*

Table 156 : Information Sources in This Report

Table 157 : Glossary of Terms Used in the Biosimilars Market

Table 158 : Accord BioPharma Inc.: Company Snapshot

Table 159 : Accord BioPharma Inc.: Product Portfolio

Table 160 : Accord BioPharma Inc.: News/Key Developments, 2024

Table 161 : Alvotech: Company Snapshot

Table 162 : Alvotech: Financial Performance, FY 2022 and 2023

- Table 163 : Alvotech: Product Portfolio
- Table 164 : Alvotech: News/Key Developments, 2024
- Table 165 : Amgen Inc.: Company Snapshot
- Table 166 : Amgen Inc.: Financial Performance, FY 2022 and 2023
- Table 167 : Amgen Inc.: Product Portfolio
- Table 168 : Amgen Inc.: News/Key Developments, 2022-2023
- Table 169 : Amneal Pharmaceuticals LLC.: Company Snapshot
- Table 170 : Amneal Pharmaceuticals LLC.: Financial Performance, FY 2022 and 2023
- Table 171 : Amneal Pharmaceuticals LLC.: Product Portfolio
- Table 172 : Amneal Pharmaceuticals LLC.: News/Key Developments, 2023-2024
- Table 173 : Biocon Biologics Ltd.: Company Snapshot
- Table 174 : Biocon Biologics Ltd.: Financial Performance, FY 2022 and 2023
- Table 175 : Biocon Biologics Ltd.: Product Portfolio
- Table 176 : Biocon Biologics Ltd.: News/Key Developments, 2022-2024
- Table 177 : Biogen: Company Snapshot
- Table 178 : Biogen: Financial Performance, FY 2022 and 2023
- Table 179 : Biogen: Product Portfolio
- Table 180 : Biogen: News/Key Developments, 2023-2024
- Table 181 : Celltrion Inc.: Company Snapshot
- Table 182 : Celltrion Inc.: Financial Performance, FY 2022 and 2023
- Table 183 : Celltrion Inc.: Product Portfolio
- Table 184 : Celltrion Inc.: News/Key Developments, 2023-2024
- Table 185 : Coherus BioSciences: Company Snapshot
- Table 186 : Coherus BioSciences: Financial Performance, FY 2022 and 2023
- Table 187 : Coherus BioSciences: Product Portfolio
- Table 188 : Coherus BioSciences: News/Key Developments, 2024
- Table 189 : Fresenius Kabi AG: Company Snapshot
- Table 190 : Fresenius Kabi AG: Financial Performance, FY 2022 and 2023
- Table 191 : Fresenius Kabi AG: Product Portfolio
- Table 192 : Fresenius Kabi AG: News/Key Developments, 2024
- Table 193 : Lilly: Company Snapshot
- Table 194 : Lilly: Financial Performance, FY 2022 and 2023
- Table 195 : Lilly: Product Portfolio
- Table 196 : Lilly: News/Key Developments, 2022-2023
- Table 197 : Pfizer Inc.: Company Snapshot
- Table 198 : Pfizer Inc.: Financial Performance, FY 2022 and 2023
- Table 199 : Pfizer Inc.: Product Portfolio
- Table 200 : Pfizer Inc.: News/Key Developments, 2023
- Table 201 : Samsung Bioepis: Company Snapshot

Table 202 : Samsung Bioepis: Product Portfolio

Table 203 : Samsung Bioepis: News/Key Developments, 2023-2024

Table 204 : Sandoz Group AG: Company Snapshot

Table 205 : Sandoz Group AG: Financial Performance, FY 2022 and 2023

Table 206 : Sandoz Group AG: Product Portfolio

Table 207 : Sandoz Group AG: News/Key Developments, 2024

Table 208 : Teva Pharmaceutical Industries Ltd.: Company Snapshot

Table 209 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2022 and 2023

Table 210 : Teva Pharmaceutical Industries Ltd.: Product Portfolio

Table 211 : Teva Pharmaceutical Industries Ltd.: News/Key Developments, 2023-2024

Table 212 : Viatris Inc.: Company Snapshot

Table 213 : Viatris Inc.: Financial Performance, FY 2022 and 2023

Table 214 : Viatris Inc.: Product Portfolio

Table 215 : Viatris Inc.: News/Key Developments, 2022

List Of Figures

LIST OF FIGURES

- Summary Figure : Share of Global Market for Biosimilars, by Region, 2023
- Figure 1 : Snapshot of the Market Dynamics for Biosimilars
- Figure 2 : Share of Global Market for Biosimilars, by Product Type, 2023
- Figure 3 : Global Biosimilar Monoclonal Antibodies Market, by Region, 2021-2029
- Figure 4 : Global Recombinant Growth Factors Biosimilars Market, by Region, 2021-2029
- Figure 5 : Global Recombinant Hormones Biosimilars Market, by Region, 2021-2029
- Figure 6 : Global Fusion Protein Biosimilars Market, by Region, 2021-2029
- Figure 7 : Global Other Biosimilars Market, by Region, 2021-2029
- Figure 8 : Share of Global Market for Biosimilars, by Therapeutic Application, 2023
- Figure 9 : Global Cancer and Related Disorders Market in Biosimilars, 2021-2029
- Figure 10 : Global Cancer and Related Disorders Market in Biosimilars, by Region, 2021-2029
- Figure 11 : Global Autoimmune and Inflammatory Diseases Market in Biosimilars, 2021-2029
- Figure 12 : Global Autoimmune and Inflammatory Diseases Market in Biosimilars, by Region, 2021-2029
- Figure 13 : Global Diabetes Market in Biosimilars, 2021-2029
- Figure 14 : Global Diabetes Market in Biosimilars, by Region, 2021-2029
- Figure 15 : Global Anemia Market in Biosimilars, 2021-2029
- Figure 16 : Global Anemia Market in Biosimilars, by Region, 2021-2029
- Figure 17 : Global Growth Hormone Deficiency Market in Biosimilars, 2021-2029
- Figure 18 : Global Growth Hormone Deficiency Market in Biosimilars, by Region, 2021-2029
- Figure 19 : Global Other Diseases Market in Biosimilars, 2021-2029
- Figure 20 : Global Other Diseases Market in Biosimilars, by Region, 2021-2029
- Figure 21 : Share of Global Market for Biosimilars, by Region, 2023
- Figure 22 : Global Biosimilars Market, by Region, 2021-2029
- Figure 23 : Share of North American Market for Biosimilars, by Country, 2023
- Figure 24 : U.S. Biosimilars Market, 2021-2029
- Figure 25 : Canadian Biosimilars Market, 2021-2029
- Figure 26 : Mexican Biosimilars Market, 2021-2029
- Figure 27 : Share of European Market for Biosimilars, by Country, 2023
- Figure 28 : German Biosimilars Market, 2021-2029
- Figure 29 : U.K. Biosimilars Market, 2021-2029

- Figure 30 : French Biosimilars Market, 2021-2029
- Figure 31 : Italian Biosimilars Market, 2021-2029
- Figure 32 : Spanish Biosimilars Market, 2021-2029
- Figure 33 : Rest of European Biosimilars Market, 2021-2029
- Figure 34 : Share of Asia-Pacific Market for Biosimilars, by Country, 2023
- Figure 35 : Chinese Biosimilars Market, 2021-2029
- Figure 36 : Japanese Biosimilars Market, 2021-2029
- Figure 37 : Indian Biosimilars Market, 2021-2029
- Figure 38 : Australian Biosimilars Market, 2021-2029
- Figure 39 : South Korean Biosimilars Market, 2021-2029
- Figure 40 : Rest of Asia-Pacific Biosimilars Market, 2021-2029
- Figure 41 : Snapshot of the ESG Pillars
- Figure 42 : Advantages of ESG for Biosimilar Companies
- Figure 43 : Share of Biotech Companies Providing ESG Disclosure, 2022
- Figure 44 : Share of ESG Disclosure, by Location, 2022
- Figure 45 : Alvotech: Revenue Share, by Country/Region, FY 2023
- Figure 46 : Amgen Inc.: Revenue Share, by Country/Region, FY 2023
- Figure 47 : Amneal Pharmaceuticals LLC.: Revenue Share, by Business Unit, FY 2023
- Figure 48 : Biocon Biologics Ltd.: Revenue Share, by Business Unit, FY 2023
- Figure 49 : Biocon Biologics Ltd.: Revenue Share, by Country/Region, FY 2023
- Figure 50 : Biogen: Revenue Share, by Business Unit, FY 2023
- Figure 51 : Biogen: Revenue Share, by Country/Region, FY 2023
- Figure 52 : Fresenius Kabi AG: Revenue Share, by Business Unit, FY 2023
- Figure 53 : Lilly: Revenue Share, by Business Unit, FY 2023
- Figure 54 : Lilly: Revenue Share, by Country/Region, FY 2023
- Figure 55 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2023
- Figure 56 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2023
- Figure 57 : Sandoz Group AG: Revenue Share, by Business Unit, FY 2023
- Figure 58 : Sandoz Group AG: Revenue Share, by Country/Region, FY 2023
- Figure 59 : Teva Pharmaceutical Industries Ltd.: Revenue Share, by Country/Region, FY 2023
- Figure 60 : Viatris Inc.: Revenue Share, by Business Unit, FY 2023
- Figure 61 : Viatris Inc.: Revenue Share, by Country/Region, FY 2023

I would like to order

Product name: Biosimilars: Global Markets

Product link: <https://marketpublishers.com/r/BDF3F38FC4FEN.html>

Price: US\$ 4,650.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BDF3F38FC4FEN.html>